BLSM is BlossomHill Therapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $20.02. Market cap: $582M.
Stock snapshot
| Price | $20.02 |
| Market cap | $582M |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About BLSM
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
Related non-dividend companies
Other non-dividend stocks investors research alongside BLSM. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is BLSM's current stock price?
BLSM (BlossomHill Therapeutics, Inc.) is currently trading at $20.02.
Does BLSM pay a dividend?
BLSM (BlossomHill Therapeutics, Inc.) does not currently pay a regular dividend.
Track BLSM in DiviDrip
Add BLSM to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search BLSM and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-04. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.